Clinical trial
Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine…
NCT00086099 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00086099 |
|---|---|
| Title | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia |
| Official title | A Phase IB/II, Randomized, Open-Label, Multicenter Study Evaluating Whether the Addition of Amifostine (Ethyol®) Will Enable the Safe Increase in Dose Intensity of Idarubicin in Combination With Cytosine Arabinoside in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Idarubincin and Amufostine (Ethyol), Idarubincin |
| Enrollment | 54 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Jun 25, 2004 |
| Last update posted | Jan 29, 2009 |
| Countries | Israel, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: